Daily Health Headlines

Doctors May Not Be Telling High-Risk Patients About HIV Prevention Drug

👤by Robert Preidt 0 comments 🕔Tuesday, October 11th, 2016

MONDAY, Oct. 10, 2016 (HealthDay News) -- Many gay and bisexual men don't know about a drug therapy that can protect them from HIV, a new study suggests.

A once-a-day pill known as PrEP -- short for pre-exposure prophylaxis medication -- has been found to reduce HIV infection by 92 percent in people at high risk for the AIDS-causing virus, including men who have unprotected gay sex, the researchers said.

The researchers studied 2014 data from 401 HIV-negative gay and bisexual men in Baltimore. Only 42 percent knew about PrEP. Those who had been tested for HIV in the previous year were more likely to be aware of it.

But having recently seen a doctor or getting tested for another sexually transmitted disease did not increase the likelihood that gay or bisexual men knew about the preventive drug, the researchers from the Johns Hopkins Bloomberg School of Public Health found.

The findings suggest many health care providers don't discuss PrEP with gay and bisexual men and other high-risk patients, even though the U.S. Centers for Disease Control and Prevention recommends the therapy for them.

"Doctors have limited time with their patients, but with gay and bisexual male patients, physicians definitely need to make it a point to discuss HIV risks and whether PrEP is a good option," said study leader Julia Raifman. She is a postdoctoral fellow in the department of epidemiology.

"Health care providers may be unfamiliar with PrEP or may be uncomfortable broaching sexual health topics with their patients. Whatever the reason, we need to find a way to get PrEP to the people who can most benefit," Raifman said in a Hopkins news release.

"PrEP could be a game-changer for HIV in the United States, where there are more than 44,000 new cases of HIV every year -- but only if people know about it," she said.

In 2011, the rate of HIV infection among gay and bisexual men in the United States was 18 percent.

Since the U.S. Food and Drug Administration approved PrEP in 2012, only 5 percent of high-risk people have taken it for HIV prevention, according to the researchers.

The study findings were published online recently in the American Journal of Preventive Medicine.

-- Robert Preidt

Article Credits / Source

Robert Preidt / HealthDay

Robert Preidt wrote this story for HealthDay. HealthDay provides up to the minute breaking health news. Click here to view this full article from HealthDay.

SOURCE: Johns Hopkins University, news release, Oct. 5, 2016

View More Articles From Robert Preidt 🌎View Article Website

Sponsored Product

Lunar Sleep for $1.95

Lunar Sleep for $1.95

People who have trouble sleeping typically have low levels of melatonin, so melatonin supplements seem like a logical fix for insomnia. There is a high demand for sleep aids, especially in the U.S. The National Health Interview Survey done in 2002, and again in 2007, found 1.6 million US adults were using complementary and alternative sleep aids for insomnia. Lunar Sleep was a top choice. Use Promo Code: Sleep2014 and only pay $1.95 S&H.

Get Lunar Sleep for $1.95

More HIV Articles

Drug Combo Shows Early Promise for Remission of HIV

Drug Combo Shows Early Promise for Remission of HIV0

THURSDAY, Nov. 10, 2016 (HealthDay News) -- Animal research with an experimental two-drug therapy could hold clues for creating long-term HIV remission in people living with the virus, a new report says. The goal: to free patients from the need ...

Antibodies May Hold Key to HIV Suppression

Antibodies May Hold Key to HIV Suppression0

WEDNESDAY, Nov. 9, 2016 (HealthDay News) -- Antibodies may keep the HIV virus in check and one day let patients stop taking antiretroviral drugs, two new preliminary trials suggest. Researchers tried to quell HIV in 23 patients with infusions ...

Experimental Medicine Might Rescue People With Drug-Resistant HIV

Experimental Medicine Might Rescue People With Drug-Resistant HIV0

FRIDAY, Oct. 28, 2016 (HealthDay News) -- Researchers report that a new medication might revolutionize the treatment of HIV patients who don't respond to existing drugs. The intravenous drug, known as ibalizumab, is given every two weeks. It's ...

Study Discounts Myth of 'Patient Zero' in U.S. AIDS Crisis

Study Discounts Myth of 'Patient Zero' in U.S. AIDS Crisis0

WEDNESDAY, Oct. 26, 2016 (HealthDay News) -- Using genetic analyses of 40-year-old blood samples, scientists have arrived at a clearer understanding of the introduction and spread in North America of the virus that causes AIDS. One myth already ...

HIV May Hide in Tissues, Even After Treatment

HIV May Hide in Tissues, Even After Treatment0

WEDNESDAY, Oct. 26, 2016 (HealthDay News) -- HIV patients who've been treated with antiretroviral drugs still have the AIDS-causing virus in their tissues, a new study suggests. Treatment with antiretrovirals eliminates detectable levels of HIV ...

View More HIV Articles


Write a Comment

Your email address will not be published. Required fields are marked *

Our Mailing List

Subscribe to our mailing list to get the latest health news as it breaks!

Your information will not be shared with anyone!